Mast cell activation: beyond histamine and tryptase.

brain fog comorbidities diagnosis inflammatory mediators mast cells mastocytosis mechanism treatment

Journal

Expert review of clinical immunology
ISSN: 1744-8409
Titre abrégé: Expert Rev Clin Immunol
Pays: England
ID NLM: 101271248

Informations de publication

Date de publication:
06 2023
Historique:
medline: 23 5 2023
pubmed: 9 4 2023
entrez: 8 4 2023
Statut: ppublish

Résumé

Mast cells are found in all tissues and express numerous surface receptors allowing them to sense and respond to allergic, autoimmune, environmental, neurohormonal, pathogenic and stress triggers. Stimulated mast cells are typically called 'activated' but the mechanisms involved and the mediators released can vary considerably. Mast cell activation diseases (MCADs) include primary, secondary and idiopathic conditions, especially mast cell activation syndrome (MCAS), but mast cells are activated in many other disorders making the diagnosis and treatment challenging. Mast cells can release numerous biologically active mediators, some of which are prestored in secretory granules while others are newly synthesized and released without degranulation. Most of the emphasis has so far been on secretion of histamine and tryptase, which do not explain all the multisystemic symptoms experienced by patients with MCADs. As a result, drug development has focused on antiproliferative therapy or blocking the action of individual mediators and not on inhibitors of mast cell activation. Activated mast cells are involved in the pathogenesis of MCADs, but also in other disorders making appropriate diagnosis and treatment challenging. The definition of mast cell activation should be expanded beyond histamine and tryptase, with an emphasis on better detection and treatments.

Identifiants

pubmed: 37029958
doi: 10.1080/1744666X.2023.2200936
doi:

Substances chimiques

Histamine 820484N8I3
Tryptases EC 3.4.21.59

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

639-654

Auteurs

Theoharis C Theoharides (TC)

Institute for Neuro-Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, USA.
Department of Immunology, Tufts University School of Medicine, Boston, MA, USA.

Adam I Perlman (AI)

Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.

Assma Twahir (A)

Institute for Neuro-Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, USA.

Duraisamy Kempuraj (D)

Institute for Neuro-Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH